Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post percutaneous coronary intervention could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis vertebral artery stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinfeng Liu
• Treatments: Argatroban; Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• For Extracranial vertebral Artery lesion, stenting was considered for symptomatic stenosis≥50% or asymptomatic stenosis≥70%;

• Successfully had intracranial or extracranial artery stenting.

Exclusion Criteria:

• Evidence of hemorrhagic brain infarction, intracranial and extracranial hematoma, or intraventricular hemorrhage, or Gastrointestinal ulcers in 3 months

• Hypersensitivity to contrast agent

• Malignant hypertension

• Difficult to perform the vertebral artery stenting

• Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc.

• Difficult to hand follow-up visit